Skip to main content
    I

    Iterum Therapeutics PLC (ITRM)

    Official site

    BIOTECHNOLOGY

    $0.03
    +0.00 (+0.00%)

    Last updated: Nov 06, 2026 at 4:00 PM ET

    Iterum Therapeutics PLC (ITRM) Financials: Revenue, Profit and Cash Flow

    Updated Nov 14, 2025. Financial statements from company filings, amounts in US dollars.

    Iterum Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2024. That year, net income was -$24.77M, operating cash flow was -$26.77M and free cash flow was -$26.77M. The quarter ended Sep 30, 2025 had revenue of $390.00K and net income of -$8.98M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $18.70M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0-100.0%N/AN/AN/A
    Dec 2019$37.00K-95.7%100.0%-275732.4%-278729.7%
    Dec 2018$869.00K+71.1%100.0%-8810.0%-8867.2%
    Dec 2017$508.00KN/A100.0%-5798.2%-5788.6%
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$0$37.00K$869.00K$508.00K$0
    Cost of revenue$254.00K$1.75M$1.80M$2.10M$161.00KN/A$0$29.90M$0
    Gross profit-$254.00K-$1.75M-$1.80M-$2.10M-$161.00K$37.00K$869.00K$508.00K$0
    Research and development$10.46M$38.24M$15.82M$8.61M$20.91M$90.77M$68.65M$25.50M$10.10M
    Operating income-$18.70M-$47.47M-$30.38M-$24.54M-$32.13M-$102.02M-$76.56M-$29.45M-$13.36M
    Net income-$24.77M-$38.37M-$44.43M-$91.56M-$52.01M-$103.13M-$77.06M-$29.41M-$13.46M
    EBITDAN/A-$34.58MN/AN/AN/A-$101.67M-$76.02M-$29.39M-$13.35M
    Fiscal years ended Dec 2016 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$390.00K$0$0$0$0$0$0$2.62M$0$0$0$0
    Gross profit$370.00K-$696.00K-$342.00K-$239.00K$0-$8.00K-$7.00K-$440.00K-$436.00K-$438.00K-$436.00K-$439.00K
    Operating income-$7.38M-$5.53M-$3.71M-$3.67M-$4.89M-$3.98M-$6.16M-$11.43M-$16.68M-$10.82M-$8.53M-$7.93M
    Net income-$8.98M-$6.51M-$4.89M-$6.58M-$6.09M-$5.00M-$7.10M-$12.36M-$3.88M-$12.24M-$9.89M-$5.09M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, total debt of $45.53M exceeded cash and equivalents by $21.41M. Shareholder equity was negative, at -$4.08M, as total liabilities of $48.68M exceeded total assets of $44.59M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$44.59M$26.26M$66.83M$91.51M$32.79M$25.75M$97.87M$46.76M$26.92M
    Current assets$24.79M$25.60M$62.44M$83.27M$21.47M$4.80M$84.67M$44.17M$25.86M
    Cash and equivalents$24.13M$6.07M$21.09M$27.45M$14.57M$4.80M$44.55M$8.48M$24.81M
    Total liabilities$48.68M$32.66M$38.83M$41.27M$83.35M$51.99M$26.25M$7.26M$4.25M
    Short-term debt$14.46M$365.00K$332.00K$2.09M$7.06M$5.80M$1.02MN/AN/A
    Long-term debt$31.07M$18.96M$28.47M$24.90M$22.46M$7.63M$13.08MN/AN/A
    Shareholder equity-$4.08M-$6.40M$28.00M$50.23M-$50.56M-$26.24M$71.62M$39.49M$22.67M
    Fiscal years ended Dec 2016 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$32.50M$34.01M$32.98M$44.59M$15.92M$14.17M$19.63M$26.26M$39.73M$51.02M$58.12M$66.83M
    Total liabilities$39.88M$37.90M$35.53M$48.68M$27.43M$25.09M$25.77M$32.66M$36.30M$43.89M$39.16M$38.83M
    Cash and equivalents$11.00M$13.03M$12.65M$24.13M$13.41M$4.98M$7.39M$6.07M$4.82M$13.73M$16.83M$21.09M
    Shareholder equity-$7.38M-$3.89M-$2.55M-$4.08M-$11.51M-$10.91M-$6.15M-$6.40M$3.43M$7.13M$18.96M$28.00M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$26.77M-$39.33M-$18.47M-$15.84M-$54.53M-$81.92M-$75.89M-$30.60M-$11.30M
    Capital expenditures$2.00K$13.00K$62.00K$61.00K$11.00K$24.00K$90.00K$812.00K$812.00K
    Free cash flow-$26.77M-$39.34M-$18.54M-$15.90M-$54.54M-$81.95M-$75.98M-$31.42M-$12.11M
    Investing cash flow$18.21M$23.34M$13.96M-$54.59M-$11.00K$40.10M-$8.66M-$31.59M-$31.59M
    Financing cash flow$26.69M$1.03M-$1.82M$83.13M$64.47M$2.06M$120.84M$45.87M$20.85M
    Fiscal years ended Dec 2016 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$7.85M-$4.75M-$3.06M-$4.26M-$2.67M-$6.76M-$13.08M-$12.84M-$9.27M-$7.63M-$9.59M-$4.26M
    Capital expenditures$12.57KN/A$2.00KN/AN/A$2.00K$0N/A$3.00K$16.11K$16.00K$45.00K
    Free cash flow-$7.86MN/A-$3.06MN/AN/A-$6.76M-$13.08MN/A-$9.27M-$7.65M-$9.61M-$4.31M
    Last 12 quarters

    Frequently Asked Questions About ITRM

    What is Iterum Therapeutics' annual revenue?

    Iterum Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2024.

    Is Iterum Therapeutics profitable?

    No. Iterum Therapeutics reported net income of -$24.77M for the fiscal year ended Dec 31, 2024.

    How much free cash flow does ITRM generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$26.77M minus capital expenditures of $2.00K produced free cash flow of -$26.77M.

    How much debt does Iterum Therapeutics have?

    The balance sheet dated Dec 31, 2024 reported long-term debt of $31.07M, short-term debt of $14.46M and cash and equivalents of $24.13M.